Physician profile
Divya Verma
NPI 1194800037
$4,376.53
in general payments reported to CMS, 2019-2025
28 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $591 · 2021: $252 · 2022: $1,520 · 2023: $203 · 2024: $266 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,122.06 | 2019-2023 | Apretude, Rukobia |
| Gilead Sciences, INC. | $782.03 | 2019-2023 | |
| Janssen Biotech, INC. | $489.50 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $272.32 | 2019-2023 | Pifeltro, Delstrigo |
| Theratechnologies INC. | $215.96 | 2021-2023 | Egrifta, Trogarzo |
| Janssen Products, Lp | $209.99 | 2022 | |
| Medtronic Vascular, INC. | $173.28 | 2019 | |
| Philips North America LLC | $153.08 | 2024-2025 | (Ao0) Igt Devices Intracardiac, Ambulatory Monitoring & Diagnostics Undivided |
| Glaxosmithkline, LLC. | $109.37 | 2020-2023 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $97.74 | 2020-2022 | |
| Novo Nordisk INC | $90.43 | 2020-2022 | |
| Mylan Institutional INC. | $89.08 | 2019 | |
| Biosense Webster, INC. | $85.83 | 2019 | |
| Pfizer INC. | $75.35 | 2020-2024 | |
| Exact Sciences Corporation | $72.33 | 2024-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $61.08 | 2025 | Aveir |
| United Therapeutics Corporation | $36.53 | 2024 | Remodulin, Tyvaso, Orenitram |
| Lilly USA, LLC | $31.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.18 | 2022 | |
| Amgen INC. | $25.97 | 2020 | |
| Seqirus USA INC | $25.39 | 2024 | Fluad, Flucelvax |
| Abbvie INC. | $24.39 | 2020 | |
| Hologic Sales and Service, LLC | $23.78 | 2025 | Aptima |
| Xeris Pharmaceuticals, INC. | $19.06 | 2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $17.14 | 2020 | |
| Napo Pharmaceuticals INC | $16.98 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.94 | 2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $12.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divya Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.